|
WO2021081330A1
|
|
Anti-idiotypic antigen binding molecules and methods of use thereof
|
|
US2020397823A1
|
|
TGF-beta Receptors and Methods of Use
|
|
WO2020227177A1
|
|
Methods of administering chimeric antigen receptor immunotherapy
|
|
WO2020123691A2
|
|
Chimeric antigen receptors and car-t cells and methods of use
|
|
CA3107938A1
|
|
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
|
WO2019246563A1
|
|
Chimeric transmembrane proteins and uses thereof
|
|
KR20210014688A
|
|
Chimeric antigen receptor T cell therapy
|
|
AU2019252944A1
|
|
Chimeric receptor T cell treatment using characteristics of the tumor microenvironment
|
|
WO2019183389A1
|
|
Chimeric transmembrane proteins and uses thereof
|
|
WO2019161271A1
|
|
Modified pluripotent stem cells and methods of making and use
|
|
US2020377609A1
|
|
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
|
EP3710471A1
|
|
Modified chimeric antigen receptors and methods of use
|
|
US2020308281A1
|
|
T cell receptor antigen binding molecules and methods of use thereof
|
|
CA3084470A1
|
|
Methods of administering chimeric antigen receptor immunotherapy
|
|
WO2019060695A1
|
|
Chimeric polypeptides and uses thereof
|
|
EP3684803A1
|
|
Antigen binding molecules and methods of use thereof
|
|
AU2018334279A1
|
|
Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
|
|
TW201900870A
|
|
Method for preparing and using embryonic mesenchymal precursor cells
|
|
SG10201912624VA
|
|
Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
|
|
US2018280437A1
|
|
Chimeric antigen receptors for melanoma and uses thereof
|
